Skip to main content

Table.1 Baseline characteristics and clinical outcomes in MINOCA patients with or without hyperuricemia

From: Hyperuricemia as a prognostic marker for long-term outcomes in patients with myocardial infarction with nonobstructive coronary arteries

Variable Total (n = 1179) Normouricemia (n = 901) Hyperuricemia (n = 278) p value
Male, n (%) 867 (73.5%) 642 (71.2%) 225 (80.9%) 0.001
Age, years 55.7 ± 11.8 56.6 ± 11.1 53.0 ± 13.5  < 0.001
BMI, kg/m2 25.4 ± 3.7 25.1 ± 3.5 26.5 ± 4.3  < 0.001
STEMI, n (%) 475 (40.2%) 344 (38.1%) 131 (47.1%) 0.008
Emergent angiography, n (%) 159 (13.4%) 125 (13.8%) 34 (12.2%) 0.483
Past history     
 Hypertension 630 (53.4%) 474 (52.6%) 156 (56.1%) 0.305
 Diabetes 187 (15.8%) 151 (16.7%) 36 (12.9%) 0.129
 Dyslipidemia 686 (58.1%) 512 (56.8%) 174 (62.5%) 0.089
 Previous MI 58 (4.9%) 44 (4.8%) 14 (5.0%) 0.918
 Killip class ≥ 2, n (%) 89 (7.5%) 64 (7.1%) 25 (8.9%) 0.514
 LVEF, % 60.5 ± 7.5 60.8 ± 6.7 60.3 ± 8.4 0.112
 TIMI risk score 3.4 ± 1.3 3.3 ± 1.2 3.5 ± 1.3 0.076
Blood test     
 Uric acid, μmol/L 343.4 ± 94.2 305.1 ± 65.1 467.9 ± 59.9  < 0.001
 FBG, mmol/L 5.69 ± 1.68 5.72 ± 1.72 5.66 ± 1.63 0.630
 TG, mmol/L 1.44 (1.05, 2.00) 1.36 (1.03, 1.93) 1.67 (1.28, 2.29)  < 0.001
 TC, mmol/L 3.92 ± 0.87 3.91 ± 1.01 3.92 ± 0.91 0.760
 LDL-C, mmol/L 2.29 ± 0.76 2.29 ± 0.73 2.29 ± 0.83 0.971
 HDL-C, mmol/L 1.08 ± 0.29 1.11 ± 0.30 0.98 ± 0.24 0.001
 Creatinine, μmol/L 83.13 ± 15.89 82.92 ± 14.90 84.23 ± 17.03 0.202
 hs-CRP, mg/L 2.20 (1.03, 5.75) 2.14 (0.96, 5.80) 2.37 (1.25, 5.69) 0.128
 NT-proBNP, pg/mL 372 (112, 683) 368 (108, 672) 379 (125, 694) 0.132
 Peak TnI, ng/mL 3.24 (0.72, 6.51) 3.11 (0.65, 6.41) 3.35 (0.98, 6.93) 0.157
In-hospital medication     
 DAPT 1091 (92.5%) 837 (92.8%) 254 (91.3%) 0.396
 Statin 1130 (95.8%) 861 (95.5%) 269 (96.7%) 0.380
 Beta-blocker 860 (72.9%) 655 (72.6%) 205 (73.7%) 0.732
 ACEI or ARB 759 (64.3%) 572 (63.4%) 187 (67.2%) 0.103
CV outcomes     
 MACE 168 (14.2%) 116 (12.8%) 52 (18.7%) 0.015
 Death, nonfatal MI, stroke or revascularization 102 (8.6%) 69 (7.6%) 33 (11.8%) 0.029
 All-cause death 18 (1.5%) 11 (1.2%) 7 (2.5%) 0.123
 Nonfatal MI 41 (3.4%) 27 (2.9%) 14 (5.0%) 0.105
 Revascularization 46 (3.9%) 33 (3.6%) 13 (4.6%) 0.445
 Nonfatal stroke 12 (1.0%) 7 (0.7%) 5 (1.7%) 0.138
 Hospitalization for UA 71 (6.0%) 56 (6.2%) 15 (5.3%) 0.616
 Hospitalization for HF 48 (4.0%) 27 (2.9%) 21 (7.5%) 0.001
  1. Hyperuricemia was defined as a serum uric acid level ≥ 420 μmol/ L in males and ≥ 357 μmol/L in females. BMI: body mass index, STEMI: ST-segment elevation myocardial infarction, LVEF: left ventricular ejection fraction, TIMI: Thrombolysis in Myocardial Infarction, FBG: fasting blood glucose, TG: triglyceride, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, hs-CRP: high-sensitive C-reactive protein, NT-proBNP: N-terminal pro-B-type natriuretic peptide, TnI: Troponin I, DAPT: dual anti-platelet therapy, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor antagonist, MACE: major adverse cardiovascular events, UA: unstable angina, HF: heart failure